Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amplitude Inc (AMPL) vs Incyte Corporation (INCY) Price & Performance

Amplitude IncTrade
Incyte CorporationTrade

Price performance (Past 24H)

Key statistics

Amplitude Inc vs Incyte Corporation — how do they compare? Amplitude Inc trades at $12.56 (market cap $1.59B), while Incyte Corporation trades at $121.06 (market cap $24.54B). The key difference: Incyte Corporation is far larger — about 15.4× Amplitude Inc's market cap, and Amplitude Inc is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals.

AMPLINCY
Market Cap
$1.59B$24.54B
Sector
TechnologyHealth
52-Week High
$12.69$129.93
52-Week Low
$5.61$81.61
Enterprise Value
$1.45B$20.04B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amplitude Inc

AMPL trades at $12.38, up 1.56% with bullish technical signals from moving averages and ADX indicators. The company shows strong revenue growth reaching $343M in 2025 with a 72% gross margin, though it continues to report net losses. Recent Q2 2026 results missed EPS expectations but beat revenue estimates, with management highlighting AI analytics platform growth and enterprise customer expansion as key drivers.

While analyst consensus remains bullish with 67% buy ratings and a $12.08 price target, investors face execution risks from persistent losses, negative cash flow, and ongoing fraud investigations. The stock's valuation appears stretched at 11.6x book value, requiring successful monetization of AI initiatives to justify current levels.

Incyte Corporation

Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.

The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.

Returns comparison

Trailing returns across standard periods

About Amplitude Inc

Amplitude Inc is pioneering a new category of software called digital optimization. The company's digital optimization system serves as the command center for businesses to connect digital products to business outcomes.

Read more on AMPL

About Incyte Corporation

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Read more on INCY